Immune Oncology Research Institute, shared a post on LinkedIn:
“For years, adjuvant treatment for Stage III colon cancer has relied mainly on oxaliplatin-based chemotherapy. The phase III ATOMIC trial, led by Frank Sinicrope and colleagues and published in The New England Journal of Medicine, may change that conversation.
In patients with completely resected Stage III dMMR colon cancer, adding atezolizumab to mFOLFOX6 increased 3-year disease-free survival to 86.3%, compared with 76.2% for chemotherapy alone – translating into a 50% lower risk of recurrence or death.
The message is clinically important: immunotherapy is no longer only a metastatic-disease discussion for dMMR/MSI-H colorectal cancer. It is now entering the adjuvant setting, where the goal is cure. This also reinforces a practical point for daily oncology care: universal MMR/MSI testing should be treated as essential, not optional.”
Title: Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
Authors: Frank A. Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter R. Peters, Robert J. Behrens, Christopher H. Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Andrew B. Nixon, Lisa A. Kottschade, Emily Kathol, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Anke Reinacher-Schick, Paul Mehan, Philip J. Gold, Maged F. Khalil, Tyler Zemla, Clare Gatten, Eileen M. O’Reilly, Jeffrey A. Meyerhardt
Read The Full Article
Other articles about Immunotherapy on OncoDaily.